| A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin | |
| Wei, Lai; Zhang, Mingxiang; Xu, Min; Chuang, Wan-Long; Lu, Wei; Xie, Wen; Jia, Zhansheng; Gong, Guozhong; Li, Yueqi; Bae, Si Hyun | |
| 刊名 | Journal of Gastroenterology and Hepatology
 |
| 2016 | |
| 卷号 | 31期号:11页码:1860-1867 |
| 关键词 | asunaprevir daclatasvir efficacy hepatitis C safety |
| ISSN号 | 1440-1746 |
| DOI | 10.1111/jgh.13379 |
| URL标识 | 查看原文 |
| WOS记录号 | WOS:000388956200014;PMID:27003037 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3323948 |
| 专题 | 中南大学 |
| 作者单位 | [Wei, Lai] Peking Univ, Peoples Hosp, Beijing, Peoples R China. |
| 推荐引用方式 GB/T 7714 | Wei, Lai,Zhang, Mingxiang,Xu, Min,et al. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin[J]. Journal of Gastroenterology and Hepatology,2016,31(11):1860-1867. |
| APA | Wei, Lai.,Zhang, Mingxiang.,Xu, Min.,Chuang, Wan-Long.,Lu, Wei.,...&Mo, Ling*.(2016).A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.Journal of Gastroenterology and Hepatology,31(11),1860-1867. |
| MLA | Wei, Lai,et al."A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin".Journal of Gastroenterology and Hepatology 31.11(2016):1860-1867. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论